-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Epcoritamab, a Novel Subcutaneous Bi-Specific CD3xCD20 Antibody for the Treatment of Patients with B-NHL: From Bench to Bedside and Beyond

Program: Product Theaters
Session: Epcoritamab, a Novel Subcutaneous Bi-Specific CD3xCD20 Antibody for the Treatment of Patients with B-NHL: From Bench to Bedside and Beyond
Monday, December 7, 2020, 10:30 AM-11:30 AM

Tahamtan Ahmadi, MD, PhD

Genmab US, Inc, Princeton, NJ

Disclosures: Ahmadi: Genmab: Current Employment, Current equity holder in publicly-traded company.

See more of: Epcoritamab, a Novel Subcutaneous Bi-Specific CD3xCD20 Antibody for the Treatment of Patients with B-NHL: From Bench to Bedside and Beyond
See more of: Product Theaters